Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Kojiro, Hata"'
Autor:
Ryosuke Matsukane, Hiroyuki Watanabe, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Nobuaki Egashira, Yoichi Nakanishi, Isamu Okamoto, Ichiro Ieiri
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract The liver is an essential organ for regulating innate and acquired immunity. We hypothesized that the pre-treatment hepatic function affects the clinical outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). W
Externí odkaz:
https://doaj.org/article/0a7d6f81e7e64dc4972a52085db8699f
Autor:
Ryosuke Matsukane, Hiroyuki Watanabe, Haruna Minami, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Satohiro Masuda, Isamu Okamoto, Takashi Nakagawa, Takamichi Ito, Masatoshi Eto, Masaki Mori, Yoichi Nakanishi, Nobuaki Egashira
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Immune checkpoint inhibitors (ICIs) play a central role in various cancers. ICIs can cause immune-related adverse events (irAEs). As severe irAEs can be life-threatening, biomarkers for estimating irAE onset are crucial. The neutrophils-to-l
Externí odkaz:
https://doaj.org/article/4857e2d4ada54864923faf8dce2aa62b
Autor:
Mayako Uchida, Tsutomu Nakamura, Kojiro Hata, Hiroyuki Watanabe, Yasuo Mori, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Keiko Hosohata, Toshihiro Miyamoto, Koichi Akashi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 4, Iss 1, Pp 1-7 (2018)
Abstract Background Antiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma r
Externí odkaz:
https://doaj.org/article/fcd939c3c29646b088ba6b3e4cc0c2f9
Autor:
Ryosuke Matsukane, Kimitaka Suetsugu, Kojiro Hata, Keisuke Matsuda, Satoshi Nakao, Haruna Minami, Hiroyuki Watanabe, Takeshi Hirota, Nobuaki Egashira, Ichiro Ieiri
Publikováno v:
International Journal of Clinical Oncology.
Autor:
Huanlin Wang, Noboru Harada, Kojiro Hata, Shinji Itoh, Katsuya Toshida, Tomonari Shimagaki, Tomoharu Yoshizumi, Hiroyuki Watanabe, Yoshihiro Nagao, Takeshi Kurihara, Yoko Makihara, Masaki Mori, Takeo Toshima
Publikováno v:
Surgery Today. 52:441-448
Lenvatinib (LEN) is a molecular-target drug, used for unresectable hepatocellular carcinoma (HCC). It is associated with adverse events (AEs), including hypertension, proteinuria, fatigue, and anorexia, which may force dose reduction or discontinuati
Autor:
Kousuke Hashimoto, Toshihiro Irisa, Shigeru Ishida, Kojiro Hata, Kazue Nakashima, Hiroyuki Watanabe, Toshikazu Tsuji, Nobuaki Egashira, Ichiro Ieiri
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 47:200-207
Autor:
Takamasa Hotta, Shunichi Hamaguchi, Tamio Okimoto, Yoshihiro Amano, Kojiro Hata, Taishi Nagao, Kazuhisa Nakashima, Takeshi Isobe, Noriaki Kurimoto, Megumi Hamaguchi, Seiko Tanaka, Mika Nakao, Yukari Tsubata, Yuki Mitarai, Akari Tanino, Takae Okuno
Publikováno v:
The Journal of Medical Investigation. 68:260-264
Background : Although platinum-combination chemotherapy is widely used to treat advanced non-small cell lung cancer (NSCLC), not all elderly patients benefit from this regimen. In this retrospective study, we aimed to evaluate whether the Glasgow Pro
Autor:
Satohiro Masuda, Tomoharu Yoshizumi, Masatake Tanaka, Ichiro Ieiri, Yoko Makihara, Motoyuki Kohjima, Kimitaka Suetsugu, Kojiro Hata, Nobuaki Egashira, Hiroyuki Watanabe, Shinji Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:803-813
This study aimed to examine the association between the trough plasma concentration of lenvatinib with the objective response rate (ORR) and adverse events in patients with hepatocellular carcinoma (HCC). Twenty-one patients with HCC who received len
Autor:
Yoichi Nakanishi, Kojiro Hata, Ryosuke Matsukane, Isamu Okamoto, Ichiro Ieiri, Hiroyuki Watanabe, Kimitaka Suetsugu, Toshikazu Tsuji, Nobuaki Egashira
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
The liver is an essential organ for regulating innate and acquired immunity. We hypothesized that the pre-treatment hepatic function affects the clinical outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). We analyze
Autor:
Yoichi Nakanishi, Yoshimasa Shiraishi, Hiroyuki Watanabe, Yasuto Yoneshima, Hiroyuki Inoue, Kentaro Tanaka, Kojiro Hata, Isamu Okamoto, Satohiro Masuda, Kohei Otsubo, Taishi Harada, Eiji Iwama
Publikováno v:
Lung Cancer. 130:5-9
Objectives To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death–1 (PD-1) inhibitors in patients with advanced non–small cell lung cancer (NSCLC). Patients and methods Clinical data in